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In the last decade, tuberculosis (TB) has
reemerged as one of the leading causes of death
(nearly 3 million deaths annually) (1). The
estimated 8.8 million new cases every year
correspond to 52,000 deaths per week or more
than 7,000 each day, which translates into more
than 1,000 new cases every hour, every day (2,3).
These death rates, however, only partially depict
the global TB threat; more than 80% of TB
patients are in the economically productive age of
15 to 49 years. The emergence of AIDS and
decline of socioeconomic standards contribute to
the disease’s resurgence in industrialized
countries (4). In most developing countries,
although the disease has always been endemic,
its severity has increased because of the global
HIV pandemic and extensive social restructuring
due to rapid industrialization and conflicts. A
major public health problem worldwide, TB is
now a global emergency (Figure 1).
Short-course chemotherapy forms the back-
bone of antitubercular chemotherapy (5). Proper
prescriptions and patient compliance almost
always cure. In fact, TB incidence was steadily
declining in most industrialized countries, until
the trend was reversed (6). Further contributing
to the increased death rate is the emergence of
new strains of M. tuberculosis resistant to some
or all current antitubercular drugs. The
resistance is attributed primarily to improper
prescriptions or patient noncompliance and is
often a corollary to HIV infection (7-9).
Multidrug-resistant TB (MDRTB), associated
with high death rates of 50% to 80%, spans a
relatively short time (4 to 16 weeks) from
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Multidrug-resistant strains of Mycobacterium tuberculosis seriously threaten
tuberculosis (TB) control and prevention efforts. Molecular studies of the mechanism of
action of antitubercular drugs have elucidated the genetic basis of drug resistance in M.
tuberculosis.  Drug resistance in M. tuberculosis is attributed primarily to the
accumulation of mutations in the drug target genes; these mutations lead either to an
altered target (e.g., RNA polymerase and catalase-peroxidase in rifampicin and
isoniazid resistance, respectively) or to a change in titration of the drug (e.g., InhA in
isoniazid resistance). Development of specific mechanism–based inhibitors and
techniques to rapidly detect multidrug resistance will require further studies addressing
the drug and drug-target interaction.
Figure 1. Global incidence of tuberculosis. Of the
estimated 8.8 million cases worldwide, more than 40%
of the cases are in Southeast Asia; India has
approximately 53.3% of those cases. A, Americas; Afr,
Africa; WP, Western Pacific; E, Europe; M, Eastern
Mediterranean; and SEA, Southeast Asia; Ind,
Indonesia; B, Bangladesh; Thai, Thailand; My,
Myanmar. *Others include Bhutan, 0.05%; Nepal,
1.2%; Maldives, 0.001%; Sri Lanka, 1%; DPR Korea,
1.2%. (Data from reference 2).196 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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diagnosis to death (10). Delayed recognition of
drug resistance, which results in delayed
initiation of effective therapy, is one of the major
factors contributing to MDRTB outbreaks,
especially in health-care facilities (11,12). In
most countries, MDRTB has increased in
incidence and interferes with TB control
programs, particularly in developing countries,
where prevalence rates are as high as 48%
(13,14). The high infection and death rates pose
an urgent challenge to rapidly detect cases.
In the past few years, genetic and molecular
insights have unraveled the mechanisms in-
volved in the acquisition of drug resistance by
Mycobacterium tuberculosis (MTB), concomitant
with the development of various molecular
strategies to rapidly detect MDRTB. In this
review, we examine the status of the mechanisms
of resistance to antitubercular drugs.
MDRTB and the Mechanisms of
Resistance
Currently TB is treated with an initial
intensive 2-month regime comprising multiple
antibiotics—rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA), and ethambutol (EMB) or
streptomycin (SM)—to ensure that mutants
resistant to a single drug do not emerge (15). The
next 4 months, only RIF and INH are
administered to eliminate any persisting tubercle
bacilli. INH and RIF, the two most potent
antituberculous drugs, kill more than 99% of
tubercule bacilli within 2 months of initiation of
therapy (16,17). Along with these two drugs, PZA,
with a high sterilizing effect, appears to act on
semidormant bacilli not affected by any other
antitubercular drugs (18). Using these drugs in
conjunction with each other reduces antitubercu-
lar therapy from 18 months to 6 months.
Therefore, the emergence of strains resistant to
either of these drugs causes major concern, as it
leaves only drugs that are far less effective, have
more toxic side effects, and result in higher death
rates, especially among HIV-infected persons.
The phrase “MDR state” in mycobacteriology
refers to simultaneous resistance to at least RIF
and INH (19) (with or without resistance to other
drugs). Genetic and molecular analysis of drug
resistance in MTB suggests that resistance is
usually acquired by the bacilli either by
alteration of the drug target through mutation
(20) or by titration of the drug through
overproduction of the target (21). MDRTB results
primarily from accumulation of mutations in
individual drug target genes (Table). The
probability of resistance is very high for less
effective antitubercular drugs such as thiaceta-
zone, ethionamide, capreomycin, cycloserine, and
viomycin (10-3); intermediate for drugs such as
INH, SM, EMB, kanamycin, and p-amino
salicylic acid (10-6); and lowest for RIF (10-8)
(22,23). Consequently, the probability of a
mutation is directly proportional to the bacterial
load. A bacillary load of 109 will contain several
mutants resistant to any one antitubercular drug
(24). Because the mutations conferring drug
resistance are chromosomal, the likelihood of a
mutant being simultaneously resistant to two or
more drugs is the product of individual
probabilities; thus the probability of MDR is
multiplicative. Resistance to a drug does not
confer any selective advantage to the bacterium
unless it is exposed to that drug (19). Under such
circumstances, the sensitive strains are killed
Table. Gene loci involved in conferring drug-resistance in Mycobacterium tuberculosis
Reported frequency
in resistant
Drug Gene Product strainsa (%) Reference
Rifampicin rpoB B-subunit of RNA polymerase >95 45-48,68-71
Isoniazid katG Catalase-peroxidase    60-70 39-48
oxyR-ahpC Alky hydro-reductase ~20 36
INH-Ethionamide inhA Enoyl-ACP reductase <10 46-48
Streptomycin rpsL Ribosomal protein S12    60 46-48
rrs 16s rRNA <10 113-117
Fluoroquinolone gyrA DNA gyrase >90 107
Pyrazinamide pncA Amidase    70-100 92-94
Ethambutol embCAB EmbCAB    69 88
aMutation frequencies are as determined by sequencing and polymerase chain reaction-single strand conformational
polymorphism (PCR-SSCP) analysis.197 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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and the drug-resistant mutants flourish. When
the patient is exposed to a second course of drug
therapy with yet another drug, mutants resistant
to the new drug are selected, and the patient may
eventually have bacilli resistant to two or more
drugs. Serial selection of drug resistance, thus, is
the predominant mechanism for the development
of MDR strains; the patients with MDR strains
constitute a pool of chronic infections, which
propagate primary MDR resistance. In addition
to accumulation of mutations in the individual
drug target genes, the permeability barrier
imposed by the MTB cell wall can also contribute
to the development of low-level drug resistance.
Studies addressing resistance to SM have found
evidence of such a two-step mechanism for the
development of drug resistance (119,120).
Resistance to INH
INH (isonicotinic acid hydrazide, 4-
pyridinecarboxylic acid hydrazide), highly active
against the MTB complex (M. tuberculosis, M.
bovis, M. africanum, and M. microti), has very
low MICs (0.02  µg/ml to 0.06  µg/ml) (25). The
mechanism of action of INH, as well as
mechanisms conferring INH resistance, are
complex and not completely understood (Figure
2). However, evidence suggests that INH inhibits
the biosynthesis of cell wall mycolic acids (long-
chain  a-branched ß-hydroxylated fatty acids),
thereby making the mycobacteria susceptible to
reactive oxygen radicals and other environmental
factors. Activation of INH to an unstable
electrophilic intermediate requires the enzyme
catalase-peroxidase (KatG, coded by katG) and an
electron sink (hydrogen peroxide) (26), although
hydrazine formed after INH spontaneously
decomposes may also mediate activation of INH
(27). Nevertheless, KatG is the only enzyme capable
of activating INH, and consequently, KatG mutant
MTB strains are invariably INH resistant.
Early studies by Middlebrook demonstrated
that INH resistance was associated with loss of
catalase activity (28). Genetic studies demon-
strated that transformation of INH-resistant M.
smegmatis and MTB strains with a functional
KatG restored INH susceptibility and put forth
the hypothesis that katG deletion may cause INH
resistance in MTB (29,30). However, in the
absence of a peroxide-inducible genetic response,
mediated in most bacteria by the transcription
factor OxyR (31), KatG is the only peroxide-
inducible MTB protein (32). Consequently, MTB
resistance to INH is paradoxical; it has to
sacrifice KatG function. MTB’s ability to adapt to
the loss of KatG function and combat organic
peroxides is remarkable. Studies conducted by
Sherman et al. demonstrated that all KatG
mutant MTB strains overexpressed a 22-kD
protein at levels significantly higher than INH-
sensitive strains (33). Sequence analysis con-
firmed that this protein was similar to the earlier
reported MTB AhpC protein. AhpC can detoxify
organic peroxides and is homologous to other
bacterial and eukaryotic proteins with alkyl
hydroperoxidase and thioredoxin-dependent per-
oxidase activities (34,35). The 5’ regions (39 to 81
bp upstream from the ahpC start codon) of each
AhpC-upregulated (and katG mutant) isolate
contained mutations that could increase pro-
moter activity; it was proposed that compensa-
tory mutations in the ahpC promoters were
selected in katG mutant strains to combat
oxidative stress (33). Subsequent studies using
immunoblotting experiments demonstrated the
consistency of AhpC upregulation among clinical
isolates with complete deletion of katG (36,37).
katG mutant isolates with variable residual KatG
Figure 2. Mechanism of action of isoniazid (INH);
acquisition of resistance and combating oxidative
stress. DPR, divergent promoter region.198 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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activity did not have this strict linear relation-
ship. Characterization of the oxyR-ahpC region
further demonstrated that mutations responsible
for AhpC upregulation occurred at low frequen-
cies and were primarily G>C to A>T transitions
localized in the oxyR-ahpC intervening region
(36). Although the sequence alterations in the
oxyR-ahpC region were predominantly restricted
to INH-resistant isolates, not all alterations
detectably increased the AhpC levels. The
apparent rarity of AhpC upregulation among
INH-resistant and katG mutant isolates could be
attributed partially to the rare occurrence of
MTB strains with complete katG deletion (38-
41,44). Alternatively, among katG mutant
isolates, selection of AhpC upregulatory muta-
tions may be subject to the selective pressure
exerted by residual catalase-peroxidase activity
(36). However, AhpC upregulation was not
observed among MTB isolates with katG315
codon mutations, which reportedly lead to more
than a 20-fold decrease in KatG activity and
confer high MICs against INH (>90  µg/ml) (42,
43). This inconsistency and rarity of AhpC
upregulation among katG mutant INH-resistant
isolates indicates a more complex relationship
between the two and underlines the need for in-
depth studies to determine precisely the
conditions regulating AhpC expression.
Clinical studies to validate the paradigm of
katG deletions and INH resistance showed that
complete deletion rarely occurred (38-41). We
constructed a 35-mer oligonucleotide probe specific
for  katG gene. Southern hybridization demon-
strated the presence of katG in all INH-resistant
isolates, precluding complete deletion of katG gene
as a dominant mechanism for INH resistance (44).
Previous studies using polymerase chain reaction
(PCR) amplification had also established these
findings; sequence analysis of katG from INH-
resistant strains showed randomly distributed
mutations, including point mutations and deletions
and insertions of up to 1 to 3 bases (38-41). These
mutations could disrupt the katG gene, leading to
the production of an inactive gene product or a gene
product with compromised peroxidative activity.
PCR amplification of the katG gene followed by
single strand conformational polymorphism (SSCP)
detected mobility shifts supporting the presence
of these mutations and thereby INH resistance.
Our analysis of the katG gene by PCR-SSCP
resulted in the amplification of the 237 bp
fragment of the katG gene and demonstrated a
67.3% (n = 19) correlation between mutations in
the  katG gene and INH resistance (45). The
results were consistent with those from earlier
studies indicating that katG gene mutations had
a correlation rate of less than 60% to 70% with
INH resistance (46-48). Sequence analysis of
INH-resistant strains demonstrating altered
SSCP patterns showed that the most common
mutation was G>T transversion in codon 463
(42). In this G>T change, Leu is substituted for
Arg, and the restriction site for NciI and MspI is
lost (40). Polymorphism in the katG locus can
then be easily detected by restriction digestion.
Recent kinetic and spectroscopic studies have
demonstrated striking similarities between KatG
from wild-type strains and the R463L mutant
isolates (49). Both enzymes had similar visible and
electron-paramagnetic-resonance spectra and simi-
lar ability to oxidize INH and inactivate InhA.
Further, when the INH-resistant katG-defective
strains of M. smegmatis with wild-type katG or the
R463L katG were transformed, INH susceptibility
was restored to about the same extent (50). These
similarities do not support the contention that the
R463L mutation of katG allows discrimination
against INH as a substrate and thereby confers
resistance to INH. Although the exact role of the
R463L mutation of katG requires further scrutiny,
this mutation may be a frequent polymorphism and
may not affect INH susceptibility.
Other common mutations resulting in an
attenuated KatG have been identified primarily
as missense mutations that result in single amino
acid substitutions (46-48). While the data point
towards mutations in the katG gene as the
dominant mechanism for INH resistance, they
also point to other factors that could mediate
MTB acquisition of resistance to INH.
Mutations in the oxyR regulon, from which
AhpC is divergently transcribed, could explain
the acquisition of INH resistance in the
remaining INH-resistant isolates (33,51). OxyR
confers high-level intrinsic resistance to INH in
Escherichia coli and Salmonella Typhimurium;
mutations in the oxyR or AhpC restore INH
susceptibility in these species (51). The MTB
oxyR regulon is much smaller than in M. leprae
and other mycobacteria—because of two impor-
tant deletions of 29 bp and 372 bp (32,52). In
addition to these deletions, the oxyR regulon
carries many frame shift mutations, which result
in low expression of this regulon and eventually
lead to low-level expression of AhpC (consistent199 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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with the finding of low-level expression of AhpC
in INH-sensitive strains vs. INH-resistant
strains) (33). A related member of the genus
resistant to INH, M. leprae, however, has a
complete  oxyR-ahpC region that is transcription-
ally fully active and may play a role in the
detoxification of active INH intermediates (52).
By analogy, therefore, the loss of the OxyR
function, in conjunction with its putative effects
on ahpC expression, could explain the exquisite
specificity of INH for the MTB complex. However,
evidence from recent studies does not indicate a
direct role for oxyR or the ahpC genes in
determining susceptibility to INH (36,37).
Polymorphisms in oxyR do not have any
preferential predisposition and exist among both
INH-resistant and -susceptible isolates with
about the same frequency (36). The relationship
of AhpC overexpression to INH resistance is more
complex. Earlier observations based on transfor-
mation of M. smegmatis strains suggested a
possible involvement of AhpC overexpression in
acquiring INH resistance (53). Transformation of
M. smegmatis isolates with multicopy constructs
of ahpC led to almost a fivefold increase in the
MIC for INH. However, an increasing body of
evidence precludes any direct role of AhpC in
determining INH susceptibility among MTB
isolates. MTB transformants bearing multicopy
constructs of ahpC did not demonstrate
significant increase in the MIC for INH, thus any
direct role for AhpC in acquisition of INH
resistance was ruled out (37).
Efforts to determine the factors involved in
resistance to INH led to the discovery of the inhA
locus, which was proposed as the primary target
for coresistance to INH and ethionamide (54).
This locus is composed of two open reading
frames (ORFs), designated orf1 and inhA,
separated by a 21-bp noncoding region. InhA, an
enoyl-ACP reductase (55), more than 40%
homologous to the EnvM protein, catalyzes an
early step in fatty acid synthesis among
enterobacteria. Like EnvM, InhA activity is also
thought to use NAD(H) as cofactor. INH
susceptibility could result from incorporation of
iso-NAD, which is formed as a consequence of the
action of KatG on INH, and thus hinders the
enzymatic activity of InhA and blocking fatty acid
synthesis (56). A T>G transversion, observed in
few of the resistant strains, at position 280 in the
inhA gene, results in the ser94 to ala94
replacement (54). This replacement, thought to
alter the binding affinity of InhA to NAD(H),
ultimately results in INH resistance (57).
Alternatively, because of mutations in the
putative promoter region, hyperexpression of
InhA could result in INH resistance.
Studies conducted in clinical settings to
provide corroborating evidence of mutations in
the inhA locus and INH resistance have shown
approximately 10% correlation (46-48). Analysis of
37 INH-resistant isolates by Kapur et al.
demonstrated no ser94-ala94 substitution in the
resistant isolates. Only one isolate had a missense
mutation: ATC>ACC at position 47, resulting in
substitution of Ile16 by Thr16. Morris et al. also
demonstrated the lack of mutations in the inhA
gene among 42 INH-resistant MTB isolates.
However, five of the INH-resistant isolates showed
single nucleotide mutations in the putative inhA
regulatory region upstream of orf1.
Subsequent biochemical characterization of
InhA function demonstrated that it catalyzed the
reduction of 2-trans-octenoyl-acyl carrier protein
and also that protein of enoyl CoA esters (58-590,
thereby acting at the final step in chain
elongation in fatty acid synthesis (58). This
observation contradicted earlier biochemical
evidence suggesting that an enzyme involved in
the synthesis of an unsaturated 24-carbon fatty
acid was the target for activated INH (60,61).
Thus, the targets identified biochemically and by
complementation of M. smegmatis are different.
Lipid pulse labeling experiments demonstrated
that the lipid biosynthetic response of M.
smegmatis and MTB after exposure with INH
were different (62), indicating a different
mechanism of action for the INH intermediate in
the two species. Transformation of M. smegmatis
with single-copy alleles of mutant inhA loci did
not result in significant resistance to INH,
indicating the presence of a different promoter in
M. smegmatis. Further, the inability of multicopy
vector constructs bearing the inhA gene to
significantly increase the MIC for INH provided
substantiating evidence for the limited involve-
ment of this locus in mediating INH resistance
among MTB isolates. These data, along with
clinical evidence, preclude the likelihood that inhA
is the primary target for the activated form of INH.
Functional  characterization of inhA muta-
tions, occurring with katG mutations (as
observed in isolates with very high MICs) (46) in
relation to lipid metabolism of INH-resistant
isolates, could perhaps resolve this discrepancy200 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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and delineate the roles of the respective loci in the
mechanism of action of INH and subsequent
acquisition of drug resistance.
In summary, mutations in the katG and the
inhA genes are associated with approximately 70%
to 80% of INH-resistant MTB isolates; molecular
mechanisms operating in the remaining isolates
are still unknown. The role of the MTB cell wall as
an important permeability barrier needs to be
explored in greater detail, particularly with
reference to INH resistance (56).
Resistance to RIF
RIF, first introduced in 1972 as an
antitubercular drug, is extremely effective
against MTB. It has MICs of 0.1  µg to 0.2  µg
(16,63). Because of its high bactericidal action,
RIF, along with INH, forms the backbone of
short-course chemotherapy (5). Although rare,
resistance to RIF is increasing because of
widespread application and results in selection of
mutants resistant to other components of short-
course chemotherapy. In this context, resistance
to RIF can be assumed to be a surrogate marker
for MDRTB (19). RIF had long been believed to
target the mycobacterial RNA polymerase and
thereby kill the organism by interfering in the
transcription process (64). Using purified RNA
polymerase from M. smegmatis, strain mc2155,
Levin and Hatfull demonstrated that RIF
specifically inhibited the elongation of full-length
transcripts and had virtually no effect on the
initiation of transcription (65).
RNA polymerase, a complex oligomer
composed of four different subunits (a,ß,ß’and s,
encoded by rpoA, rpoB, rpoC, and rpoD,
respectively), is highly conserved among bacte-
rial species (66). Characterization of the rpoB
gene in E. coli demonstrated that RIF specifically
interacted with the ß subunit of RNA polymerase,
thereby hindering transcription, and that muta-
tions in the rpoB locus conferred conformational
changes leading to defective binding of the drug and
consequently resistance (67). Subsequently, the
rpoB locus from MTB was characterized and
mutations conferring the resistant trait were
identified (Figure 3; 68-71). Most mutations were
determined to be restricted to an 81-bp core region
and are dominated by single nucleotide changes,
resulting in single amino acid substitutions,
although inframe deletions and insertions also
occur at lower frequencies. Changes in the codons
Ser531 and His526 have been documented in more
than 70% of the RIF-resistant isolates. A very small
number of mutations in RIF-resistant isolates do
not map in this 81-bp core region; it is speculated
that additional mechanisms, including RIF
permeability and mutations in alternate subunits
of RNA polymerase, may also be involved in
conferring the resistance phenotype.
Figure 3. Single amino acid substitutions in the 81 bp core-region of the rpoB gene responsible for conferring
rifampicin (RIF) resistance (Insertions and deletions that confer the RIF-resistance phenotype are not depicted).
Amino acids are represented with single letter abbreviations. Changes in codon Ser531 and His526 account for
more than 70% of the mutations with RIF resistance (depicted in shaded ellipses).201 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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The consistency of mutations in the rpoB
locus and the RIF- resistant phenotype (>95%)
has marked clinical implications. Because it may
act as a surrogate marker for MDRTB, RIF
resistance has prompted development of various
diagnostic tests to improve the sensitivity of
mutation detection. Although automated se-
quencing has been unambiguously applied to
characterize mutations associated with RIF
resistance, a number of other techniques such as
PCR-SSCP (41,45-48,121), dideoxy fingerprint-
ing (72), heminested PCR (73), PCR heteroduplex
analysis (70), and line probe hybridization (74,75)
have been successfully applied to detecting these
mutations. Such novel strategies to detect drug-
resistant MTB isolates have been described
elsewhere (76). PCR-SSCP analysis for detection
of mutations responsible for conferring drug-
resistance is increasingly useful. In particular,
the development of nonisotopic PCR-SSCP
analysis has simplified the procedure, enhancing
its utility in routine laboratories (41,45).
However, results obtained with SSCP analysis
should be interpreted with caution as the
technique only detects mutations and gives no
information on the nature of associated mutation.
For example, silent mutations in the rpoB gene
have been identified that give altered mobility
patterns on SSCP analysis but have no
association with RIF resistance, which under-
lines the need for caution in interpreting results
and phenotypic or genotypic correlation (77).
Resistance to EMB
EMB [dextro-2,2’-(ethyldiimino)-di-1onol],
synthetic compound with profound
antimycobacterial effects (78), is a first-line anti-
MTB drug with a broad spectrum of activity,
unlike INH. EMB is also advocated in
disseminated  M. avium complex infections,
particularly in HIV-infected persons (79). Until
recently, EMB’s mechanism of action and the
genetic basis for resistance to it were largely
obscure. Specificity of EMB for mycobacterial
species, however, indicated that its target may
have been involved in the construction of the outer
cell wall. Synergy resulting from coadministration
of EMB and other drugs gave further evidence for
the involvement of EMB in obstructing the
formation of cell wall. The synergistic effect was
explained as a consequence of increased permeabil-
ity of the mycobacterial cell wall leading to
increased drug uptake (80,81). Indeed, earlier
studies of Takayama and colleagues demonstrated
that administration of EMB led to rapid cessation of
mycolic acid transfer to the cell wall and equally
rapid accumulation of trehalose mono- and di-
mycolates (82,83). Mycolic acids attach to the 5’-
hydroxyl groups of D-arabinose residues of
arabinogalactan  and form mycolyl-arabinogalactan-
peptidoglycan complex in the cell wall. Disruption
of the arabinogalactan synthesis inhibits the
formation of this complex and may lead to increased
permeability of the cell wall. Subsequently, it was
demonstrated that EMB specifically inhibited
arabinogalactan synthesis (84).
A breakthrough was achieved in defining the
precise cellular target for EMB with the isolation
and identification of ß-D-arabinofuronosyl-1-
monophosphoryl decaprenol (DPA), which accu-
mulates rapidly (less than 2 minutes) on
exposure of EMB- sensitive cells to EMB (86).
DPA is an arabinosyl donor; cell-free assay
systems developed for DPA established that it
was one of the major intermediates of arabinan
synthesis. It was later shown that EMB
specifically inhibited arabinosyl transfer, sug-
gesting that arabinosyl transferase was the
primary cellular target for EMB (Figure 4).
Identification of arabinosyl transferase as
the primary target for EMB helped unravel the
Figure 4. Mechanism of action of ethambutol (adapted
from 84-88). EMB interacts with the EmbCAB proteins
encoded by the embC, embA, and embB genes, leading to
inactivation of arabinogalactan synthesis. Mutations in
the  embB locus cause alterations in EmbB, possibly
leading to an altered target for EMB. Alternatively,
hyperexpression of the EmbCAB proteins could lead to
EMB resistance. Inlet box: Organization of the emb
operon in Mycobacterium tuberculosis (MTB).202 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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genetic basis for EMB resistance. Using target
overexpression by a plasmid vector, Belanger et
al. cloned the emb locus from an EMB-resistant
strain of M. avium (86). Transformation of this
emb locus conferred resistance to M. smegmatis
mc2155 strain and also demonstrated that the
level of resistance conferred depended on the
copy number of the gene, which was consistent
with the notion of drug resistance due to target
overexpression. Site-directed mutagenesis and
overlapping clone analysis localized a 9.8-kb
EMB resistance locus, subsequently shown to be
ubiquitous among mycobacteria. Sequence analy-
sis of this locus revealed three complete ORFs—
designated embR, embA, and embB. The embR
ORF is separated by a 178 bp divergent promoter
region from the embA and embB ORFs.
Characterization of the embR ORF showed that
the region was strongly homologous with a family
of transcriptional activators of Streptomyces and
thus could play a role in modulating the
expression of embA and embB. Importantly, the
embB ORF lacks a potential ribosome binding
site and is thus translationally coupled to embA,
which suggests that a heterodimeric enzyme
complex may be the target for EMB. Mapping
studies further demonstrated that both embA
and embB, along with the divergent promoter
region, were essential to EMB resistance.
In contrast to the organization of the emb
locus in M. avium, molecular genetic approaches
applied to MTB revealed a highly conserved 14-
kb region comprising three homologous ORFs
designated embC, embA, and embB preceded by a
predicted coding region and by orfX (which
encodes a putative protein belonging to the short
chain alcohol dehydrogenase family) (87). Primer
extension analysis of the emb region supported the
notion of its organization as an operon and further
indicated the polycistronic nature of its transcripts.
The emb genes are translationally coupled the
absence of any untranslated intercistronic region
between the emb genes so indicated). However, the
presence of a secondary stem loop structure
between the embA and the embB genes  indicates
that the embB gene in MTB could be differentially
regulated. The embCAB proteins are believed to
be integral membrane proteins, consistent with
their role in the synthesis of various arabinan-
linkage motifs of the arabinogalactan and
lipoarabinomannan (86,87).
Identification of the embCAB genes prompted
a detailed analysis of the molecular mechanisms
responsible for conferring resistance to EMB in
MTB isolates. Preliminary studies documented
among EMB-resistant isolates missense substi-
tutions in the conserved embB codon 306 that
coded for methionine; their role in conferring
resistance to EMB was confirmed by gene tranfer
assays (87). Recent analysis of the embCAB
region has confirmed the predominance of embB
Met306 substitutions among EMB-resistant
clinical isolates of MTB (approximately 89%
among EMB-resistant isolates with single amino
acid substitutions) (88). Sequence analysis of 118
clinical isolates of MTB showed five mutants of
the embB codon 306, all leading to substitution of
Met with Val, Leu, or Ile. MTB strains with
Met306Leu and Met306Val substitutions demon-
strated a higher MIC for EMB (40 µg/ml) than
those for organisms with Met306Ile substitutions
(20 µg/ml). The embB codon 306 may contain
important structure-function information; struc-
tural alterations in this codon may have a
detrimental effect on the interaction of EMB and
EmbB, thereby resulting in a EMB-resistant
phenotype.
Sequence alterations in the embCAB region
correlate with  approximately 70% of EMB-
resistant strains. Overexpression of the EmbB
protein has been documented to mediate resistance
in  M. smegmatis (87), and a homologous
mechanism may operate in MTB, perhaps
accounting for the remaining 30% of the EMB-
resistant isolates. A full understanding of the
mechanisms for acquisition of EMB resistance
among these isolates requires further studies.
Resistance to PZA
PZA, a structural analog of nicotinamide, was
shown to have considerable anti-MTB activity in
1952, but it became an important component of
short-course chemotherapy only in the mid-
1980s. PZA, active against semidormant bacilli
not affected by any other drug, has strong
synergy with INH and RIF and shortens the
chemotherapeutic schedule for antitubercular
treatment from 9 to 12 months to 6 months (15).
Depending on the assay system and conditions
applied, MICs of PZA vary from 8  µg/ml to 60  µg/
ml. However, even at very high MICs, PZA has no
significant bactericidal effect and is primarily
considered a “sterilizing drug” (18). Activity of
PZA is highly specific for MTB; PZA has scant or
no effect on other mycobacteria, including M.
bovis, which demonstrate high-level intrinsic203 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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resistance to PZA (89). Naturally resistant strains
of  M. bovis lack the enzyme Pzase, which
hydrolyzes PZA to pyrizinoic acid, the presumed
active form of PZA (90,91). PZA in this context is
similar to INH; it is transported as a neutral species
into the cell, where it is converted into its active
form. This notion was strengthened by evidence
provided by in vitro studies that demonstrated the
susceptibility of PZA-resistant MTB and M. bovis
to pyrizinoic acid. MTB Pzase has both
pyrazinamidase and nicotinamidase activities
(90). Using sequence information of E. coli
nicotinamidase, Scorpio and Zhang  isolated the
mycobacterial  pncA gene, which codes for the
amidase (92). Characterization of the pncA gene
from M. bovis isolates identified a single point
mutation that results in the substitution of His to
Asp at position 57. This substitution results in the
production of an ineffective Pzase in M. bovis
strains. Point mutations in the pncA gene of PZA-
resistant MTB strains were also identified.
Substitution of Cys138 with Ser, Gln141 with
Pro, and Asp63 with His and deletion G
nucleotide at positions 162 and 288 resulted in a
defective Pzase. Transformation of Pzase-
resistant strains with functional construct of
MTB  pncA gene restored susceptibility to PZA,
providing further evidence that mutations in the
pncA gene were responsible in conferring the
resistant phenotype. Subsequent characteriza-
tion of the pncA gene from clinical isolates of MTB
confirmed these findings (93,94). Mutations
including missense alterations, nucleotide inser-
tions or deletions, and termination mutations
have been found in the pncA gene from PZA-
resistant MTB isolates. These sequence alter-
ations are interspersed along the entire length of
the  pncA gene, demonstrate limited degree of
clustering, and vary in frequency from 70% to 100%
(93,94). The absence of correlating mutations in the
pncA gene from PZA- resistant MTB isolates
indicates that perhaps at least one additional
mechanism mediates resistance to PZA.
The cellular target for PZA, however, has not
been identified, although the apparent similarity
of PZA to nicotinamide suggests that enzymes
involved in pyridine nucleotide biosynthesis are
probable targets. Implication of the pncA gene in
conferring PZA-resistant phenotype has pro-
found clinical applications. Application of PCR-
SSCP for detection of mutations in the pncA gene
could help circumvent the difficulties in
determining PZA susceptibilities (96) and rapidly
discriminate  between MTB and M. bovis (96).
Resistance to Fluoroquinolones (FQ)
FQs as antimycobacterial agents were first
described in 1984 and have primarily been used
as therapeutic alternatives in MDRTB cases (97).
DNA gyrase (Gyr), a member of the type II DNA
topoisomerases (98), is the primary target for FQ
action. Gyr introduces negative supercoils in closed
circular DNA molecules and is a heterotetramer
(A2B2), coded by gyrA and gyrB respectively
(99,100). Quinolone sensitivity is determined by the
GyrA protein, which contains the cleavage/
religation activity (100), while GyrB contains the
intrinsic coumarin-sensitive ATPase activity (101).
FQs, synthetic derivatives of nalidixic acid,
act by inhibiting DNA supercoiling and relax-
ation activity of Gyr without affecting the ATPase
activity (102) and enhance the rate of DNA
cleavage by Gyr. Quinolone-mediated cleavage of
double-stranded DNA results in a 4 bp 5’
overhangs on either strand, to which GyrA
subunits become attached covalently by O4
phosphotyrosine bond (103). Gyr catalyzes the
cutting of DNA, denaturation of the overhang,
and strand separation. The exact mechanism of
inhibition of Gyr activity with respect to
quinolones remains unknown. However, quinolone
drugs bind with a greater affinity to single-
stranded DNA than double-stranded DNA and
possibly do not bind to Gyr at all (104).
Consequently, by binding to the single-
stranded DNA, the quinolones may inhibit
religation, thereby imposing an effective
transcriptional block (105), culminating in
cellular death. However, questions about the
specific interaction of quinolones and the Gyr/
DNA complex remain unsolved (106).
Cloning and expression of the MTB gyrA and
gyrB genes allowed mapping of mutations that
confer resistance to FQs (107). Mutations were
found to be clustered in a small region in GyrA
that is close, approximately 40 residues amino-
terminal, in the linear amino acid sequence to the
active site tyrosine, Tyr122 (E. coli numbering)
(108). Other single amino substitutions, for
residues 88 to 94, were also identified in
ciprofloxacin-resistant MTB isolates (Figure 5).
Because polymorphism encountered at codon 95
(Ser95>Thr95) occurred in both resistant and
susceptible isolates, it may not be involved in204 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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acquiring the FQ-resistant phenotype. Alterna-
tive mechanisms to gyrA mutations, including
changes in cell wall permeability and active
quinolone efflux pumping, have also been
proposed and could account for the low-level
resistance among MTB isolates.
Newer FQ derivatives such as sparfloxacin
have shown greater anti-MTB potency (MIC = 0.2
µg/ml) than ciprofloxacin and ofloxacin, giving
hope for better therapeutic alternatives for
MDRTB. However, FQ susceptibility in the
treated patient population must be continuously
monitored to prevent low-level FQ-resistant
strains from acquiring additional mutations that
lead to high-level resistance (109).
Resistance to Streptomycin and Other
Inhibitors Of Protein Synthesis
Various drugs exert their antibacterial
effects by inhibiting the protein transitional
machinery. Among these, aminoglycosides,
macrolides, tetracyclines, and basic peptides like
viomycin and capreomycin are active against
mycobacteria (110). SM, one of the oldest drugs
known to be active against MTB, disrupts the
decoding of aminoacyl-tRNA and thus inhibits
mRNA translation or causes inefficient transla-
tion (111). One of the most common mechanisms
for acquisition of resistance to SM is acetylation
of the drug by aminoglycoside-modifying en-
zymes (111,112). However, this mechanism is not
found in MTB. Instead, resistance to SM is
attributed, at least partially, to two distinct
classes of mutations including point mutations in
S12 ribosomal protein, encoded by rpsL gene
(113), and mutations in the rrs operon encoding
the 16S rRNA (114).
Point mutations in the rpsL gene result in
single amino acid substitutions (114-117) that
affect higher order structures of 16S rRNA and
thereby confer SM resistance. Mapping of the
mutations in the rpsL gene demonstrated that
they primarily affected one of the two critical
lysine residues at positions 43 and 88 and led to
the substitution with either arginine at 88 or
arginine and threonine at position 43 (115). An
SM-resistant isolate (>60 µg/ml) showed an A>G
transversion at position 904 in the 16S rRNA
with an additional single A>C transversion in the
rpsL gene, which resulted in the substitution of
Lys-Gln at position 88 (115). Because each of the
corresponding mutations in the small subunit
rRNA or the ribosomal protein S12 confer the
resistant phenotype in E. coli, these mutations
mediated ribosomal drug resistance and were
responsible for conferring high-level SM resis-
tance. Mutations in the rpsL gene accounted for
more than two thirds of SM-resistant cases.
The genesis of SM resistance in some of the
SM-resistant isolates is due to point mutations in
the 16S rRNA. Mutations in the rrs locus have
been mapped to two regions, the 530 loop and the
915 region. Within the 530 loop, C>T transitions
at 491, 512, and 516, in addition to the A>C
transversion at position 513, are consistent with
the SM-resistant phenotype (114) pseudoknot
formation within the MTB 16S rRNA. Base
pairing between residue 524-526 (of the 530
region of the hairpin loop) and residue 504-507 (of
the adjacent 510 region bulge loop) (118) results
in SM resistance in clinical isolates of MTB (114).
Further, G-U wobble base pairing between
residues 522-501 stabilizes the pseudoknot
formation and thereby confers resistance to SM.
It can thus be concluded that SM resistance in
MTB stems from alterations of the drug target
and not by drug modification.
However, no mutations in the rpsL and the rrs
genes are detected in a significant number of SM-
resistant isolates (46,48). Curiously, intrinsically
SM-resistant strains of M. gordonae, M. szulgae,
and M. avium do not show any alterations in the
rpsL or the rrs genes, suggesting a probable third
factor in conferring SM resistance. Earlier studies
have documented the inhibitory effect of SM on
protein synthesis in vitro to the same extent as
observed in wild-type MTB strains. The same
inhibitory effect was not observed on whole cells,
Figure 5. Single-amino acid substitutions responsible
for conferring resistance to fluoroquinolones (FQ).
Mutation in the Ser95 codon (shown in stippled box),
observed in both FQ-sensitive and FQ-resistant
isolates, rules out its role in acquisition of resistance.205 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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suggesting the probable role of cell wall
permeability barrier in conferring SM resistance
(119). More recently, it has been demonstrated that
membrane-active substances augmented the MIC
for SM in strains with alterations in the rrs genes,
thus providing further evidence for a probable role
of the MTB-permeability barrier in mediating
resistance to SM (120).
Resistance to Other Drugs
Related aminoglycosides such as kanamycin,
amikacin, and paromomycin demonstrate no
obvious cross-resistance to SM and thus are
alternatives in cases of SM resistance. Viomycin
and capreomycins are bacteriostatic agents that
act by binding to the 50S ribosomal subunit and
inhibit the translocation reaction (111). Although
cross-resistance between viomycin and
capreomycin does occur, the exact mechanism for
acquisition of drug resistance is not known.
Conclusions
Molecular insights suggest that accumula-
tion of mutations in the individual drug target
genes is the primary mechanism of MDRTB.
Morris and colleagues’ investigation of the
molecular mechanisms of drug resistance in
MDR strains found that 25 of 44 SM-resistant
strains had mutations in the rpsL gene, while five
others had rrs gene perturbations (48). The rpoB
gene had mutations in 28 of 29 RIF-resistant
strains. Mutation in the katG gene was seen in 20
of the 42 INH-resistant stains, while five had
inhA gene mutations. Of the 20 MDRTB strains,
11 had mutations in genetic markers associated
with resistance to each of these three drugs.
Similarly, Heym et al. reported that
resistance to antitubercular agents in their
collection of strains resulted from alterations to
chromosomal genes encoding the drug targets;
they excluded the possibility that MDRTB
stemmed from acquisition of genes for novel
resistance determinants (46). MDR appeared to
result from the stepwise acquisition of new
mutations in the genes for different drug targets.
In all cases exactly the same mutations or
combination of mutations were observed, regard-
less of the patient’s HIV status.
Thus, the origin of MDRTB is due more to
treatment difficulties, including noncompliance
and administration of inadequate treatment
regime, and not to the emergence of novel
resistance mechanisms; this is reassuring for the
future of short-course chemotherapy. Adminis-
tration of directly observed combination chemo-
therapy (or Directly Observed Treatment Short-
Course [DOTS]) appears to be the most effective
way to ensure a decrease in primary resistance,
acquired resistance, and relapses (3). DOTS has
been successfully implemented in diverse
geographic areas including Tanzania, Guinea,
China, Bangladesh, New York City, and Peru,
which reported more than a 90% cure rate (3).
Nearly 70 countries have adapted DOTS as a part
of their national TB control programs and
achieve good cure rates. Successful implementa-
tion of DOTS in the coming decades requires not
only a concerted effort from various funding
agencies but also a strong social and political
commitment. Apart from strategic interventions
based on strong political will, grass-roots action
will have to be strengthened mainly at the
primary health-care level to check the unlimited
upsurge of this preventable fatal disease. Basic
research will have to be continually updated to
prevent the drug-resistant strains from becoming
an unmanageable clinical paradigm. DOTS
currently is our only option to reverse the global
TB epidemic and prevent MDRTB.
The inability to detect resistance early,
however, is one of the major factors involved in
the genesis and control of MDRTB; this
invariably results in prolonged exposure to drugs
that are virtually ineffective. One of the major
consequences of unraveling the genetic basis of
drug resistance in MTB is the development of
various molecular strategies to rapidly detect
MDRTB (76). However, the sheer multiplicity of
gene loci to be investigated for diagnosis of
MDRTB renders most of the approaches
mentioned above as tedious and resource-
intensive for a routine laboratory service
program, particularly in developing countries
like India, with limited resources and high
disease incidence. Resistance to most anti-MTB
drugs, with the exception of RIF, cannot be
attributed to a single locus in substantial
percentage (>90%), which is perhaps the greatest
deterrent in the development of single amplifica-
tion–based methods for rapid detection of
resistance.
Working out the exact biochemical details of
drug-drug target interaction acquires consider-
able attention in the era of MDRTB, because only
then will more rational structure- and mecha-
nism-based approaches to inhibitor design be206 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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possible. Clearly, a concerted global effort is
required to defeat TB resurgence.
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